Cardiovascular Health

New research reveals that bedtime antihypertensive dosing does not improve cardiovascular outcomes in frail older adults, emphasizing safety over timing.

Diet influences blood pressure, cholesterol levels, and overall heart function.

Pharmacists have a unique opportunity to improve cardiovascular outcomes by integrating medication management with food-as-medicine approaches.

The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy.

Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction considerations, and special management factors in patients with comorbidities.

GLP-1 receptor agonists, including semaglutide and tirzepatide, significantly reduce cardiometabolic risk factors such as dyslipidemia, type 2 diabetes, metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, chronic kidney disease, and cardiovascular events, with evidence suggesting that some of these benefits may occur independently of weight loss.

The approval is based on findings from the INSPIRE trial, where treprostinil demonstrated efficacy in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure.

The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology.

Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.

Maternal cardiometabolic issues during pregnancy significantly elevate children's blood pressure, highlighting the need for preventive health measures.

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

The 12.5-mg dose tablet enhances hypertension treatment options and reduces adverse effects for patients.

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.

At Baptist Health South Florida, pharmacists are embedded in all areas of cardiovascular care, an expert said.

A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.

Alongside regular monitoring and pharmacotherapy, key lifestyle changes can help manage and prevent high blood pressure.

Research reveals that higher levels of vitamin B12, copper, and manganese during pregnancy lower midlife blood pressure and hypertension risk.

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial and the newest ACS guidelines.

An oral dose of 0.6 mg per 5 mL of colchicine could aid individuals who have trouble with swallowing pills.

Traditional risk factors were more contributable to cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), whereas nontraditional ones were more critical for CIS with PFO.

Promoting weight management prior to pregnancy and in early life may yield stronger cardiovascular and maternal health.

Small changes in blood pressure and pulse were shown in patients of all ages, and the authors suggested that these are monitored carefully in patients being treated for ADHD.

Host Craig Beavers speaks with Steven Dunn about the latest ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.

The registry data showed that cardiac magnetic resonance (CMR) was obtained in more clinically complex patients with recurrent pericarditis.

Host Craig Beavers spoke with several presenters, researchers, and experts about the key data being discussed at the meeting.

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.